Clinical Trials Logo

Clinical Trial Summary

There is no standard approach to the treatment of vestibular migraine. Agents used in the treatment of migraine are frequently used. In treating migraine, local anesthetic agents, nerve-blocking methods, and botulinum toxin local injection is commonly applied, and successful results are obtained. Adapting the nerve-blocking method used in the treatment of migraine to the treatment of vestibular migraine is the purpose of the study.


Clinical Trial Description

Patients between 18-75 diagnosed with/without aura or chronic migraine according to IHCD-3 diagnostic criteria and who describe dizziness during or between attacks will be evaluated in the ENT clinic. Patients included in the study will be recorded as definite vestibular migraine or probable vestibular migraine according to criteria defined in the BARANY community and IHCD-3. Differential diagnosis of vertigo will be made with pure tone audiometry, Caloric test, VHIT, Videonystagmography, and cVEMP. MIDAS (migraine disability scale), DHI (dizziness handicap inventory), VSS (vertigo symptom scale), DASÖ-21 anxiety test, and Allodynia Symptom Checklist (ASKL) forms will be filled. Patients will be randomly divided into two groups. Patients in the control group will be given beta-blocker therapy, the standard treatment. The local anesthetic agent bupivacaine will be injected into the greater/small occipital nerves and supratrochlear/ supraorbital nerves. Patients in the study group will be asked to keep a diary of pain, dizziness, and painkiller use for one month. At the end of the 1st month, the scoring will be repeated, and the patients who show a decrease in half will be accepted to the next stage, botulinum toxin application. BoNT/A botulinum toxin A (botox; Allergan) will be injected bilaterally into the same regionns. All scoring will be repeated in the 1st, 3rd and 6th months. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05472675
Study type Interventional
Source Pamukkale University
Contact Fazil N Ardic, MD
Phone 902582965799
Email fnardic@pau.edu.tr
Status Recruiting
Phase N/A
Start date June 1, 2022
Completion date June 29, 2024

See also
  Status Clinical Trial Phase
Enrolling by invitation NCT04196933 - Analysis of Vestibular Compensation Following Clinical Intervention for Vestibular Schwannoma N/A
Recruiting NCT04417361 - Galcanezumab for Vestibular Migraine Phase 2
Enrolling by invitation NCT05396482 - Assesment of Hearing in Patients With Vestibular Migra
Completed NCT03979677 - Effects of Lifestyle Modification on Vestibular Migraine N/A
Completed NCT05157399 - Quantification of the Effect of the OtoBand on Objective Measures of Vertigo and Dizziness N/A
Not yet recruiting NCT05914207 - Non-Pharmacological Treatment of Vestibular Migraine in Children and Adolescent N/A
Recruiting NCT04939922 - China Headache Registry Study
Recruiting NCT05418218 - International Headache Registry Study
Suspended NCT04026516 - CAVA: Dizziness Trial N/A
Withdrawn NCT03578354 - 4-Aminopyridine, Atenolol, or Placebo in Patients With Vestibular Migraine Phase 2
Completed NCT02350985 - Comparison of Propranolol and Venlafaxine in Treatment of Vestibular Migraine Phase 4
Completed NCT03417596 - Vestibular Rehabilitation in Patients With Vestibular Migraine N/A
Not yet recruiting NCT04664088 - Acupuncture for Prophylaxis of Vestibular Migraine N/A
Enrolling by invitation NCT06267924 - SENSE-VM: Safety and Effectiveness of a Novel Medical Device for Symptom Ease in Vestibular Migraines N/A
Completed NCT05960786 - Treating the Symptoms of Vertigo in a Real-world Setting Using the OtoBand N/A
Completed NCT02447991 - Rizatriptan for Episodic Dizziness in Vestibular Migraine Phase 2/Phase 3
Recruiting NCT04935970 - Metabolic Disorders and Vertigo
Not yet recruiting NCT05508139 - The Role Of Vestibular Rehabilitation Therapy In Management Of Vestibular Migraine Patients
Completed NCT01669304 - Verapamil vs. Sertraline for Vestibular Migraine & Chronic Subjective Dizziness Phase 1
Recruiting NCT05984901 - The CAVA Multicentre Dizziness Trial N/A